Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Free heme regulates placenta growth factor through NRF2-antioxidant response signaling.

Maria G Kapetanaki | Oluwabukola T Gbotosho | Deva Sharma | Frances Weidert | Solomon F Ofori-Acquah | Gregory J Kato
Free radical biology & medicine | 2019

Free heme activates erythroblasts to express and secrete Placenta Growth Factor (PlGF), an angiogenic peptide of the VEGF family. High circulating levels of PlGF have been associated in experimental animals and in patients with sickle cell disease with echocardiographic markers of pulmonary hypertension, a life-limiting complication associated with more intense hemolysis. We now show that the mechanism of heme regulation of PlGF requires the contribution of the key antioxidant response regulator NRF2. Mimicking the effect of heme, the NRF2 agonist sulforaphane stimulates the PlGF transcript level nearly 30-fold in cultured human erythroblastoid cells. Heme and sulforaphane also induce transcripts for NRF2 itself, its partners MAFF and MAFG, and its competitor BACH1. Furthermore, heme induction of the PlGF transcript is significantly diminished by the NRF2 inhibitor brusatol and by siRNA knockdown of the NRF2 and/or MAFG transcription factors. Chromatin immunoprecipitation experiments show that heme induces NRF2 to bind directly to the PlGF promoter region. In complementary in vivo experiments, mice injected with heme show a significant increase in their plasma PlGF protein as early as 3 h after treatment. Our results reveal an important mechanism of PlGF regulation, adding to the growing literature that supports the pivotal importance of the NRF2 axis in the pathobiology of sickle cell disease.

Pubmed ID: 31408727

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NHLBI NIH HHS, United States
    Id: U01 HL117721
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL133864
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL121386
  • Agency: NHLBI NIH HHS, United States
    Id: R25 HL128640
  • Agency: NIMHD NIH HHS, United States
    Id: R01 MD009162
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL106192
  • Agency: NHLBI NIH HHS, United States
    Id: U54 HL141011

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Diagenode (tool)

RRID:SCR_014807

Commercial provider of equipment and resources for epigenetics research, biological sample preparation, and diagnostic assays. The products Diagenode provides include automation and semi-automation software, antibodies, reagents, kits, and shearing technologies.

View all literature mentions

B6.129X1-Nfe2l2tm1Ywk/J (tool)

RRID:IMSR_JAX:017009

Mus musculus with name B6.129X1-Nfe2l2tm1Ywk/J from IMSR.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

K-562 (tool)

RRID:CVCL_0004

Cell line K-562 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions